Open AccessTreatment of comorbid chronic obstructive pulmonary disease and cardiovascular disease
Author(s) -
Н. Т. Ватутин,
А. С. Смирнова
Publication year - 2016
Publication title -
pulʹmonologiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.126
H-Index - 6
eISSN - 2541-9617
pISSN - 0869-0189
DOI - 10.18093/0869-0189-2016-26-3-364-371
Subject(s) - medicine , comorbidity , copd , cardiorespiratory fitness , chronic bronchitis , intensive care medicine , disease , pulmonary disease , adverse effect , bronchitis , physical therapy
This review provided recent information about treatment of patients with comorbid respiratory and cardiovascular disease. Cardiorespiratory comorbidity is associated with cross"deterioration of the disease course given similar pathogenic components. This could decrease effects of treatment, worsen prognosis and actually requires new approaches to diagnosis and therapy. While choosing the treatment strategy for a patient with comorbid chronic obstructive pulmonary disease (COPD) and cardiovascular disease, a physician should be aware of the pooled risk of adverse events. Some agents widely used for treatment of cardiovascular diseases could worsen the course of COPD and, vice versa, bronchodilators that are the essential component of therapy of chronic obstructive bronchitis could adversely affect the cardiovascular system. Therefore, medication choice could be significantly limited due to comorbidity.